Medical Xpress

NOVEMBER 21, 2022

In a new study published in Circulation: Genomics & Precision Medicine, Mayo Clinic researchers designed and developed the first suppression-replacement KCNH2 gene therapy for correcting both long QT syndrome (LQTS) and short QT syndrome (SQTS).

Gene Therapy 72

Gene Therapy Gene Genome Genomics 72

XTalks

APRIL 24, 2023

Awareness of rare diseases is growing, and with a better understanding of the pathophysiology of many rare diseases, innovative treatment options are emerging, like gene therapies that can treat the root cause of rare genetic diseases and potentially provide long-term symptom relief, or even a definitive cure.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

pharmaphorum

AUGUST 5, 2021

A recent clinical research paper highlights the importance of targeting of PPIs in stem cells of cancer. The combination of the PPI database and the ‘high-throughput gene profiles’ revealed a cluster of colon cancer stem cell (CSCs) related genes. . What does this mean for clinical research?

Protein 126

Protein Gene Bioassay DNA 126

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

XTalks

MAY 23, 2024

Eterovic brings much knowledge and experience to the table, having led the development of a new Oncology Diagnostic program at Eurofins Viracor that integrates the latest genomic profiling techniques. Eterovic highlights that the financial and logistical barriers to comprehensive genomic profiling are high but not impossible to overcome.

Genetics 114

Genetics Research Genome Genomics 114

Cloudbyz

AUGUST 9, 2023

The clinical research landscape is rapidly evolving. As it becomes more complex with growing volumes of data, evolving regulations, and the pressure for faster drug development, traditional methods of clinical research management are no longer sufficient. This is where the platform approach comes into play.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Roots Analysis

MARCH 24, 2022

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix- omics including, transcriptomics, genomics, proteomics and metabolomics. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Web: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

Cloudbyz

JULY 31, 2024

This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care. These therapies involve modifying a patient’s cells or genes to treat or prevent diseases, with the promise of long-lasting effects.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

WCG Clinical

NOVEMBER 17, 2023

It also establishes the role of the Institutional Biosafety Committee (IBC) in providing local oversight of such research. This change expanded the definition of HGT research to include research using nucleic acids that are able to replicate, be transcribed, translated into protein, and/or integrate into the host genome.

Genome 52

Genome Genomics Gene Editing Genetic Engineering 52

pharmaphorum

JULY 4, 2022

And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar. It is a forefront of the work that we are doing at IQVIA.”.

Genome 105

Genome Genomics Research Medicine 105

WCG Clinical

AUGUST 27, 2024

However, newer ones continue to emerge as technologies advance, and IBCs today are tasked with reviewing some of the most complex and debated research taking place, including genome editing and the use of gene drive-modified organisms. Question: Why do community members need to participate in IBC review meetings?

Genetic Engineering 52

Genetic Engineering Engineer Compliance Genetics 52

The Pharma Data

JANUARY 10, 2021

Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin dosing patients. Clinical trial materials are being manufactured by Editas Medicine. CAMBRIDGE, Mass.,

Medicine 52

Medicine Development Clinical Trials Clinical Trials 52

pharmaphorum

MAY 18, 2022

Genomics has unlocked entirely new insights to what exactly may cause certain neurological conditions. Also, there is particular emphasis on exploring the potential of gene therapy to develop targeted treatments for these and further neurodegenerative conditions.

Gene Therapy 92

Gene Therapy Gene Genetics Development 92

XTalks

FEBRUARY 27, 2024

There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

XTalks

MARCH 25, 2021

Biomedical Research and Technologies : Presenting the latest biomedical research from both industry and academia, including preclinical studies as well as technological innovations in genomics, single cell analysis, proteomics, metabolomics and much more.

Life Science 105

Life Science HR Clinical Trials Clinical Trials 105

XTalks

SEPTEMBER 12, 2023

Biomedical Research and Technologies: Get access to the most recent biomedical research news from both industry and academia, including preclinical studies and technological breakthroughs in genomics, single cell analysis, proteomics, metabolomics and much more.

Life Science 105

Life Science Branding Clinical Trials Clinical Trials 105

XTalks

JUNE 18, 2024

XTALKS CLINICAL EDGE: Issue 2 — Elixirgen Therapeutics’ Interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials.

Protein 52

Protein RNA Genetics Gene Expression 52

XTalks

MAY 23, 2024

With over 25 years of experience, Dr. Duke’s expertise in growth and bone disorders has been instrumental in advancing clinical research and improving patient outcomes. Advancements in genomic technology, precision medicine and gene therapy offer hope for personalized treatments and improved outcomes.

Clinical Trials 52

Clinical Trials Clinical Trials Hormones Trials 52

Trialfacts

SEPTEMBER 12, 2024

About the Research Center: Boston Children’s Hospital The research enterprise at Boston Children’s Hospital, involving over 3,000 researchers, is the largest in the world at a pediatric center. This includes the pathogenesis of Atopic Dermatitis Location What’s Next?

Research 52

Research Gene Editing Biobanking Bioinformatics 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

JANUARY 10, 2021

Comparing to Non-Small Cell Lung Cancer(NSCLC), it is still not clear about tumor driving gene in the development of SCLC, and thus it is lacking of targeted therapeutic treatment for this life threaten disease. SH ) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Trials 52

The Pharma Data

NOVEMBER 5, 2020

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Deep Genomics – Toronto-based Deep Genomics appointed Amanda Kay to the newly-created role of chief business officer.

Genome 40

Genome Genomics Medicine Life Science 40

The Pharma Data

JANUARY 24, 2021

It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. BT-001 is based on the patented Invir.IO

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

JANUARY 11, 2021

The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

Antibody 40

Antibody Clinical Trials Clinical Trials Trials 40

pharmaphorum

SEPTEMBER 1, 2020

Likewise, the 1964 Declaration of Helsinki put greater ethical structures on clinical research, clearly cementing the difference between production of scientific prescription medicines and other chemicals. New challenges in an age of innovation.

Medicine 145

Medicine Insulin Drugs Pharmacy 145

Pharmaceutical Technology

FEBRUARY 20, 2023

This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. What future developments are you most excited about being part of Cerba Research?

Research 130

Research Clinical Trials Clinical Trials Trials 130